Gillette
This article was originally published in The Rose Sheet
Executive Summary
Global launch of prescription drug hair removal cream Vaniqa (eflornithine 15%) to be handled by Chicago-based DDB Corbett, a joint venture between Frank J. Corbett, Inc. and DDB Chicago. The firm will handle all professional communications, direct-to-consumer advertising and Web site development of the drug product. The Vaniqa launch will begin in the U.S. and roll out to four additional countries. Gillette and Bristol-Myers Squibb filed the Vaniqa NDA Sept. 27 (1"The Rose Sheet" Oct. 11, 1999, p. 12). Under the agreement, BMS is handling the FDA submissions and clinical development and will market the prescription product in partnership with Gillette
You may also be interested in...
Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate
Ongoing studies on Bristol-Myers Squibb's newly approved Vaniqa prescription hair removal drug could broaden the target consumer of the topical cream to include men. FDA approved the product for removal of women's facial hair July 27.
Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate
Ongoing studies on Bristol-Myers Squibb's newly approved Vaniqa prescription hair removal drug could broaden the target consumer of the topical cream to include men. FDA approved the product for removal of women's facial hair July 27.
Gillette Rx Vaniqa Deal May Be Anecdote To Hairy Third Quarter - Stock Index
Gillette's joint venture with Bristol-Myers Squibb to bring the Rx product Vaniqa (eflornithine 15%) to market may be a prescription for growth following the company's rocky third quarter performance on Wall Street. The stock moved up 3/4 to 36-1/2 on Oct. 4, the day of the announcement.